Provided by Tiger Trade Technology Pte. Ltd.

Insmed

111.12
+2.532.33%
Post-market: 111.600.4800+0.43%16:41 EDT
Volume:4.13M
Turnover:452.37M
Market Cap:24.27B
PE:-27.18
High:111.54
Open:107.76
Low:105.68
Close:108.59
52wk High:212.75
52wk Low:90.39
Shares:218.38M
Float Shares:216.82M
Volume Ratio:1.78
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0882
EPS(LYR):-6.4200
ROE:-87.22%
ROA:-22.17%
PB:32.04
PE(LYR):-17.31

Loading ...

Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul

Reuters
·
Yesterday

Insmed Price Target Cut to $207.00/Share from $237.00 by Barclays

Dow Jones
·
Sep 30

Barclays Remains a Buy on Insmed (INSM)

TIPRANKS
·
Sep 30

Insmed: Brinsupri Launch Momentum Supports Overweight Rating and Unchanged $218 Price Target

TIPRANKS
·
Sep 28

Insmed Price Target Announced at $188.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

Insmed resumed with a Buy at Goldman Sachs

TIPRANKS
·
Sep 24

Mizuho Securities Sticks to Its Buy Rating for Insmed (INSM)

TIPRANKS
·
Sep 23

Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214

TIPRANKS
·
Sep 22

Insmed Rises on FDA Priority Review for Lung Disease Drug

Reuters
·
Sep 21

Insmed says FDA grants Priority Review to sNDA for Arikayce

TIPRANKS
·
Sep 21

FDA Grants Priority Review to Insmed's Snda for Arikayce® (Amikacin Liposome Inhalation Suspension) for Treatment of Mac Lung Disease with Pdufa Target Action Date Set for January 28, 2027

THOMSON REUTERS
·
Sep 21

Insmed: Brinsupri Launch Trends Support Growth Outlook; Buy Rating and $218 Price Target Reaffirmed

TIPRANKS
·
Sep 21

Insmed Price Target Cut to $198.00/Share from $212.00 by Roth Capital

Dow Jones
·
Sep 16

Movement Alert|Insmed Falls 5.04% in Regular Trading, Trading at $119.99

Market Focus
·
Sep 15

Insmed price target lowered to $198 from $212 at Roth Capital

TIPRANKS
·
Sep 15

Roth MKM Remains a Buy on Insmed (INSM)

TIPRANKS
·
Sep 15

Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)

TIPRANKS
·
Sep 13

Insmed Reports Inducement Awards of 115,320 RSUs and Stock Options Priced at USD 121.82 Per Share

Reuters
·
Sep 04

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 04

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Simply Wall St.
·
Sep 01